 |

Molecular MRI of Hematopoietic Stem-progenitor Cells: In Vivo Monitoring of Gene Therapy and Atherosclerosis CME DisclosuresRelease Date: May 13, 2008; Valid for credit through May 13, 2009 | | Physicians - maximum of 1.0 AMA PRA Category 1 Credit(s)™ for physicians |  | 
| Contents of This CME Activity |  |
| Legal Disclaimer |  |
 | The material presented here does not necessarily reflect the views of Medscape or companies that support educational programming on www.medscape.com. These materials may discuss therapeutic products that have not been approved by the US Food and Drug Administration and off-label uses of approved products. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity. Copyright © 2008 Medscape. |
|
 |

Learning Objectives Upon completion of this activity, participants will be able to: - Identify cells commonly involved in the development of atherosclerosis
- List advantages and disadvantages of the incubation method of cell labeling
- Identify methods of cell labeling with contrast agents for molecular
MRI
- Describe the imaging method for plaque-specific imaging of atherosclerosis
- Describe the potential uses of molecular MRI using labeled hematopoietic stem-progenitor cells
Authors and Disclosures
|
 |
Medscape, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Medscape, LLC designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit(s). Physicians should only claim credit commensurate with the extent of their participation in the activity.
Contact This Provider
|
 |